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Abstract
The cross-talk between the innate and the adaptive immune system is facilitated by the initial interaction of antigen with
dendritic cells. As DCs express a large array of TLRs, evidence has accumulated that engagement of these molecules
contributes to the activation of adaptive immunity. We have evaluated the immunostimulatory role of the highly-conserved
outer membrane lipoprotein P6 from non-typeable Haemophilus influenzae (NTHI) to determine whether the presence of
the lipid motif plays a critical role on its immunogenicity. We undertook a systematic analysis of the role that the lipid motif
plays in the activation of DCs and the subsequent stimulation of antigen-specific T and B cells. To facilitate our studies,
recombinant P6 protein that lacked the lipid motif was generated. Mice immunized with non-lipidated rP6 were unable to
elicit high titers of anti-P6 Ig. Expression of the lipid motif on P6 was also required for proliferation and cytokine secretion by
antigen-specific T cells. Upregulation of T cell costimulatory molecules was abrogated in DCs exposed to non-lipidated rP6
and in TLR2
2/2 DCs exposed to native P6, thereby resulting in diminished adaptive immune responses. Absence of either
the lipid motif on the antigen or TLR2 expression resulted in diminished cytokine production from stimulated DCs.
Collectively; our data suggest that the lipid motif of the lipoprotein antigen is essential for triggering TLR2 signaling and
effective stimulation of APCs. Our studies establish the pivotal role of a bacterial lipid motif on activating both innate and
adaptive immune responses to an otherwise poorly immunogenic protein antigen.
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Introduction
The initiation of a robust and long-lasting immune response to
infections and vaccination is thought to depend on effective TLR
mediated recognition and signaling on innate immune cells. TLR
stimulation in innate immune cells, such as dendritic cells and
macrophages, activates various cytokine genes that instruct the
nature of the ensuing T cell and B cell response [1]. The innate
immune cell itself is influenced by the TLR signal and results in
upregulation of T cell co-stimulatory molecules and secretion of
proinflammatory cytokines. The nature of this response orches-
trates the magnitude and quality of the ensuing T cell and B cell
response, thus effective vaccination requires potent TLR activa-
tion [2]. Vaccines against bacterial pathogens utilize conserved
outer membrane antigens, which may also serve as TLR ligands
[3,4]. The extent to which a given vaccine antigen induces potent
and sustained immune responses is likely to be dependent on
whether it or the adjuvant can stimulate both innate and adaptive
immunity. This study has examined the TLR mediated augmen-
tation of innate and adaptive immune responses to a candidate
vaccine antigen for a respiratory pathogen.
Nontypeable Haemophilus influenzae (NTHI) is a commensal
gram-negative coccobacillus that resides in the human upper
respiratory tract and causes recurring episodes of infections in
patients with chronic obstructive pulmonary disease (COPD) and
children with otitis media. Current research efforts are evaluating
the efficacy of several NTHI gene products as candidate vaccine
antigens [5]. These include the major outer membrane proteins
(P1, P2, P4, P5), adhesins, and lipoolgosaccharide. Each of the
candidate antigens tested have elicited IgA and IgG following
immunizations in murine, rat, and chinchilla models [6,7].
Protection from NTHI colonization by increased clearance of
the bacteria and reduction in accumulation of middle ear fluids
reveal the functional capacity of vaccination against molecules
expressed by NTHI. Antigenic heterogeneity in many of the
surface molecules in NTHI strains suggests that a highly
conserved, immunogenic molecule is required for formulation of
an effective vaccine.
Outer membrane protein 6 (P6) is a 16 kDa lipoprotein highly
conserved at the nucleotide and amino acid level among all tested
strains of NTHI [8]. This lipoprotein functions as an anchor
between the outer membrane and the bacterial cell due to its
association with peptidoglycan. In addition to high sequence
homology between strains, P6 also expresses epitopes on the outer
membrane accessible for antibody binding. In various models of
NTHI infection antibody responses to P6 were associated with
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responses to P6 are associated with relative protection against
NTHI infection in adults with COPD [11]. As a lipoprotein, P6
expresses a tripalmitoyl lipid motif at the N-terminus, a common
motif among bacterial lipoprotein family members [12]. The
presence of this lipid motif permits recognition of P6 by TLR2,
whose expression is found on macrophages, dendritic cells, B cells,
neutrophils, mast cells and endothelial cells [12]. The induction of
TLR2 signalling by its ligands leads to the production of
proinflammatory cytokines and mucin via NF-kB activation.
The immunogenic nature of this highly conserved lipoprotein
makes P6 a promising vaccine candidate for NTHI and prompted
our evaluation of the lipid component’s requirement and its
contribution to the immunogenicity of P6.
There is compelling evidence supporting the role of some lipid
motifs to act as adjuvants and potentiate immune responses to
otherwise poorly immunogenic proteins. Synthetic lipid motifs
coupled to peptides representing influenza viral epitopes recognized
by CD8
+ and CD4
+ T cells elicit protective immune responses.
Bacterially derived lipid motifs were the strongest immunogens. In
addition, the immunogenicity of these synthetic lipopeptides was
dependent on the position of the lipid insert onto the peptide. In
order to empirically test the importance of the lipid motif on the
generation of anti-P6 responses, a recombinant P6 variant lacking
thetripalmitoyllipid motif wasgenerated. Therefore,one important
goal of this study was to evaluate the immunogenic potential of a
non-lipidated form of P6, which still retains expression of a T cell
helper epitope. Our studies provide a detailed analysis of the pivotal
role of the lipid motif in the immunogenicity of P6 and elicitation of
anti-P6 antibodies and T cells in vivo.
Material and Methods
Mice
Female C57BL/6NCr (WT) mice were purchased from NCI.
Female B6.129-Tlr2
tm1Kir/J (H2
b) (TLR2
2/2) mice were pur-
chased from Jackson Laboratories (Bar Harbor, ME). Mice were
maintained under specific pathogen free conditions at Roswell
Park Cancer Institute and all procedures performed on animals
were approved by the Institutional Animal Care and Use
Committee, and complied with all state, federal, and NIH
regulations.
Native P6 Purification
Purification of the protein P6 from NTHI strain 1479 was
performed as previously described [9,13]. The extracted native P6
migrated as a single 16-kDa band in SDS-PAGE and was assayed
with PYROGENT-5000 (Lonza) to ensure no endotoxin contam-
ination was present in the purified protein.
Recombinant non-lipidated P6 purification
To generate purified recombinant P6 that lacks the N-terminal
tripalmitoyl lipid motif, the P6 gene was cloned into plasmid
pDEST17 (Invitrogen), which expresses the P6 protein with an N-
terminal 66 histidine tag. Recombinant non-lipidated P6 was
purified by affinity chromatography and elution from a Talon
column (BD Biosciences) as previously described [14]. The
purified protein migrated as a single band in SDS-PAGE and
was further assayed to ensure no endotoxin contamination was
present.
BMDC purification
Bone marrow from femurs and tibias of WT or TLR2
2/2 mice
was flushed out with a 21 gauge needle and complete medium
(RPMI-1640 supplemented with 4 mM glutamine, 150 mg/ml
penicillin-streptomycin, 0.2 mM non-essential amino acids, 20
mM HEPES, 1 mM sodium pyruvate, 50 mg/ml gentamycin,
50 mM2 - b-mercaptoethanol, 10% FCS). The bone marrow cells
were cultured in 6 well plates at a concentration of 2610
6 cells/
well in presence of 20 ng/ml of GM-CSF and 10 ng/ml of murine
rIL-4 (BD Pharmingen). Media was changed every 2 days and on
day 6 of culture, DCs were activated overnight with 300 ng/ml of
either purified native P6, non-lipidated rP6, or 2610
7 CFU/ml
formalin-killed NTHI. Media alone controls were also included.
Cells were analyzed next day by flow cytometry for cell surface
markers or used in a P6-specific T cell assays.
Flow cytometry
Cells were washed in FACS staining buffer (0.9 g/L NaN3,5 %
FBS in PBS) and stained for 20 min at 4uC in the dark with anti-
CD11c FITC (1:50) and anti-B7.2 PE (1:200) or anti-CD40 PE
(1:50) or anti-MHC II PE (1:200) in the presence of Fc block (all
reagents from BioLegend). Cells were washed with FACS buffer,
fixed with 2% formaldehyde, and analyzed on a FACScan flow
cytometer. The data was analyzed using WinMDI or Cell Quest
Pro.
Endocytosis analysis
Cy3-conjugated native P6 and non-lipidated rP6 were gener-
ated using the Cy3 Monoreactive Dye Pack (GE Healthcare).
Following manufacturer’s instructions, 1 mg of each antigen was
filtered into 0.1 M Na2CO3/NaHCO3 buffer and mixed with Cy3
dye for 30 min at room temperature. Free dye was separated from
the protein by filtration into PBS. Equivalent dye/protein ratios
were determined by Lowry assay (Sigma). BMDCs were pulsed
with 300 ng/ml of each conjugated antigen overnight. Harvested
BMDCs were labeled with anti-CD11c FITC and acquired by
two-color flow cytometry and ImageStream (Amnis) to determine
the extent of endocytosis. For ImageStream analysis, cells were
incubated with 100 mM LysoTracker Red (Invitrogen) for 30 min
prior to harvesting and surface staining in order to visualize
endocytosis and intracellular localization of Cy3-conjugated
antigen.
BMDCs were washed once with medium, resuspended in
complete medium at 2610
5 cell/ml and incubated either at 4uCo r
37uC for 1 hr with FITC-Dextran 40,000 MW (Sigma) at a final
concentration of 0.25 mg/ml. At the end of the incubation, cells
washed three times with FACS buffer and stained for 20 min at
4uC in the dark with anti CD11c-PE (1:400) in the presence of Fc
block. Cells were washed with FACS buffer, fixed with 2%
formaldehyde, and analyzed on a FACScan flow cytometer and
WinMDI program. The values of the MFI at 4uC (background
endocytosis) were subtracted from the MFI values obtained at
37uC.
P6-specific T cell proliferation assay
WT or TLR2
2/2 mice were immunized in the hind foot-pads
with 25 mg of native P6 emulsified with CFA (Sigma) and boosted
1 week later with antigen in IFA (Sigma). One week after the
second immunization the popliteal lymph nodes were collected
and T cells were enriched over a mouse CD3
+ enrichment
column. Lymphocytes were seeded in round bottom 96 well plates
with syngeneic irradiated BMDCs pulsed with the stimuli
described above and co-cultured for 4 days. 1 mCi of
3H-
thymidine (Perkin Elmer) was added to each well for the last
18 hrs of co-culture and the incorporation of
3H-thymidine was
analyzed with a beta-counter.
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Frequency of cytokine-secreting T cells from the spleen of P6-
immunized mice was evaluated by cytokine ELISPOTs. Multi-
screen Immobilon-P plates (Millipore) were coated overnight at
4uC with 3 mg/ml of rat anti-mouse IFN-c (AN-18), anti-mouse
IL-2 (JES6-1A12), or anti-mouse IL-4 (11B11). Lymphocytes were
co-cultured with syngeneic irradiated BMDCs pulsed with the
stimuli described above. After an 18 hr culture, the plates were
washed extensively and cytokines were detected with biotinylated
antibodies (IFN-c, R4-6A2; IL-2, JES6-5H4; IL-4, BVD6-24G2)
followed by addition of streptavidin-HRP. Spots were developed
with tetramethylbenzidine (TMB) substrate and enumerated using
a dissecting microscope.
Induction and detection of anti-P6 antibodies
WT and TLR2
2/2 mice were immunized intraperitonealy with
40 mg of native P6 or non-lipidated rP6 emulsified in CFA and
boosted one week later with antigen in IFA and two weeks later
with antigen alone. In some instances WT mice immunized with
non-lipidated rP6 also received 40 mg of recombinant Pam3Cys
(Invivogen) during each of the three immunization injections. Mice
were bled retro-orbitally on a weekly basis. Titers of P6-specific
antibodies and the associated Ig isotype and IgG subclasses were
detected via an indirect ELISA, as described previously [9,13].
Statistical analysis
The values are representative of 3 or more independent
experiments (as indicated in the legend of the figures) 6 S.E.M.
Testing for differences between means was determined using
either 1-way ANOVA or 2-way ANOVA with post-test compar-
isons, and Student t-test (as indicated). Analysis was performed
using GraphPad Prism v5.
Results
Immunization with lipid expressing P6 results in high
titers of anti-P6 Ig
The lipoprotein P6 is found in the bacterial outer membrane
and is highly conserved among all NTHI strains, thereby making it
an ideal protein target for vaccination studies. When extracted and
purified directly from the bacterial outer membrane, it retains
expression of the lipid motif. We first sought to determine whether
the presence of this lipid motif impacts the generation of antibody
titers following immunization. In order to validate the importance
of lipid expression and its contribution to the immunogenicity of
P6, we generated a recombinant version of P6 that lacks the N-
terminal tri-palmitoyl lipid motif. The amino acid sequence of the
recombinant P6 is 100% identical to native bacteria-purified P6.
Naı ¨ve mice were immunized intraperitonealy with either native P6
or non-lipidated recombinant P6. Pre-immune and post-immune
sera were collected from all mice and the magnitude and kinetics
of antibody production was monitored (Fig. 1). Mice immunized
with native P6 generated high titers of anti-P6 antibodies that were
detectable as early as 2 weeks after initial immunization. The
antibody titers reached peak levels 8 weeks after the first
immunization. In contrast, the antibody titers in mice immunized
with non-lipidated rP6 rose very modestly in the early weeks, even
though the immunization schedule utilized adjuvant. Not only
were the kinetics of anti-P6 Ig appearance slower in non-lipidated
rP6 immunized mice, the magnitude of the antibody titers in the
sera were substantially lower in comparison to mice immunized
with native P6. The average peak antibody titers of mice
immunized with non-lipidated rP6 was more than 10-fold lower
than the level observed in mice immunized with native P6. This
result suggests that the lipid motif and the nature of the
immunizing protein play an important role in generating robust
antibody titers.
In addition to measuring the kinetics and magnitude of anti-P6
Ig, we analyzed whether the difference in antibody response
following immunization with non-lipidated rP6 could be account-
ed for by an alteration in the immunoglobulin subclass that is
generated. The levels of IgM, IgA, and the four IgG subclasses that
recognized plate-bound P6 were measured at a single serum
dilution (Fig. 2). Mice immunized with native P6 did not display a
bias in the repertoire of anti-P6 IgG subclasses generated, as all
four IgG subclasses were present in mice at high levels. In contrast,
mice immunized with non-lipidated rP6 displayed a striking bias in
the IgG subclass of anti-P6 generated. Although antibodies of
IgG1 and IgG2b subclasses were present at nearly equivalent
levels in mice immunized with either non-lipidated rP6 or native
P6, mice from the former group displayed low to negligible levels
of IgG2a and IgG3 at all time points analyzed. Therefore, the
presence of a lipid motif on an immunizing antigen can and does
influence the subclass of antibody repertoire that is generated.
Figure 1. Anti-P6 Ig levels are elevated in mice immunized with P6 expressing lipid motif. Mice were immunized i.p. at one week intervals
with 40 mg of native P6 (&) or non-lipidated rP6 (N) emulsified in CFA, IFA, and PBS. Anti-P6 Ig levels were measured in pre-immune and post-
immune sera by ELISA. Results are expressed as endpoint titers of serum dilutions. *p,0.05 2way ANOVA with Bonferroni post-test comparison
between native P6 and non-lipidated rP6 at each timepoint.
doi:10.1371/journal.pone.0019781.g001
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cytokine production
The known requirement for T cell help in antibody class-
switching prompted us to evaluate the effect of the lipid motif in
antigen-specific T cell stimulation. Mice were immunized with
native P6 and then in vitro T cell responses were measured against
APC presenting either native P6 or non-lipidated rP6. CD3
+
lymph node cells were isolated and co-cultured with syngeneic
BMDCs pulsed with native P6 and non-lipidated rP6. Proliferation
of T cells in vitro by co-culture with antigen-loaded APCs was
measured by
3H-thymidine incorporation (Fig. 3A). BMDCs
pulsed with non-lipidated rP6 provided minimal stimulation of
antigen-specific T cells, whereas BMDCs pulsed with native P6
stimulated T cell proliferation at high levels.
The role of the lipid motif in eliciting cytokine production from
the activated T cells was measured by cytokine ELISPOT
(Fig. 3B). Splenocytes from native P6 immunized mice were
harvested and cultured overnight with syngeneic irradiated
BMDCs pulsed with either native P6 or non-lipidated rP6. In
concordance with the data from the proliferation assay, BMDCs
pulsed with non-lipidated rP6 were incapable of stimulating high
numbers of antigen-specific T cells to secrete cytokines. These
results lend further support to the finding that the lipidated antigen
is a strong activator of T cells.
Expression of TLR2 on APCs mediates responses to
lipoprotein P6
The striking differences between the ability of non-lipidated rP6
and native P6 to stimulate T cells and B cells prompted us to next
examine what role the lipid motif might play on maturation and
activation of dendritic cells. As TLR2 binds bacterial lipid motifs,
we examined whether this receptor plays a role in the responses of
DCs to P6. WT mice were immunized with native P6 and CD3
+ T
cellsfromlymphnodeswereisolatedand co-culturedwithsyngeneic
irradiated WT or TLR2
2/2 BMDCs pulsed with native P6, non-
lipidated rP6, or formalin-killed NTHI (NTHI f.k.). Formalin-killed
NTHI was utilized as a positive control in order to evaluate the
capacity of TLR2
2/2 APC to respond to ligands of NTHI that
signal via other TLRs. WT BMDCs presenting native P6 were
capable of eliciting T cell proliferation, whereas TLR2
2/2
BMDCs stimulated with either native P6 or non-lipidated rP6 were
unable to stimulate T cell proliferation (Fig. 4A). Importantly, this
was not a global deficiency caused by the absence of TLR2, as both
WT and TLR2
2/2 BMDCs pulsed with formalin-killed NTHI
induced T cell proliferation at similar levels. Expression of TLR2 on
DCs therefore plays an essential role in the ability of these cells
to respond to the lipid motif on P6 and activate antigen-specific T
cells.
Uptake of antigen is an early step in antigen-processing and
maturation of DCs. Immature DCs are highly endocytic and
progressively lose this ability during their maturation process. The
ability of DCs treated with native P6 to stimulate antigen-specific
T cells prompted us to evaluate how recognition of P6 via TLR2
also affects the maturation of DCs. Endocytosis of FITC-labeled
dextran was measured in stimulated BMDCs (Fig. 4B). APC that
are matured by a potent stimulus will not endocytose FITC-
dextran particles efficiently, whereas a stimulus that does not
mature the BMDCs will allow the cells to continuing sampling the
microenvironment. Native P6 stimulated WT BMDCs did not
endocytose FITC-dextran to a high degree, revealing the potent
maturation signal delivered by exposure to this stimuli. This
mature phenotype of low endocytosis is attributable to the
interaction of TLR2 with its ligand, as TLR2
2/2 BMDCs
exposed to native P6 continue to maintain high endocytic
capacity. TLR2
2/2 BMDCs could mature in the presence of
other bacterial ligands expressed by formalin-killed NTHI and
therefore exhibited reduced endocytosis of FITC-dextran. These
experiments reveal that recognition of lipoprotein P6 by TLR2 is
essential for DC maturation, as absence of either the ligand (i.e.
lipid motif) or the receptor (i.e. TLR2) did not confer a potent
maturation signal for APC.
Lipid motif promotes enhanced uptake of P6 by APCs
The difference in the ability of native P6 and non-lipidated rP6
to stimulate T cells is dependent on the maturation state of the
APC and also the amount of antigen that has been taken up by the
APC. We next evaluated whether the lipid motif might influence
the extent of antigen uptake by DC and its intracellular
localization. The level of antigen uptake was quantified using
Cy3-conjugated of native P6 and non-lipidated rP6 by Amnis
ImageStream and flow cytometry (Fig. 5). Endocytosis of native
P6 was observed in 95% of BMDCs compared to 58% of BMDCs
that had taken up non-lipidated rP6 (Fig. 5B); these values were
additionally corroborated by flow cytometric analysis. Addition-
ally, native P6 was endocytosed at nearly twice the amount of non-
Figure 2. Anti-P6 Ig isotype and subclass analysis in immu-
nized mice. Levels of Ig isotype and IgG subclass were measured by
ELISA in WT mice immunized with native P6 (&) or non-lipidated rP6
(N). OD values at 405 nm for sera dilutions at 10
22.6 (1:400) were
analyzed for levels of P6-specific IgA, IgM, IgG1, IgG2a, IgG2b, and IgG3.
*p,0.05 2way ANOVA with Bonferroni post-test comparison between
native P6 and non-lipidated rP6 at each timepoint.
doi:10.1371/journal.pone.0019781.g002
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both ImageStream (Fig. 5C) and flow cytometry analysis
(Fig. 5D). The absence of the lipid motif did not alter the
localization of the antigen in the endosomal compartment as
determined by their equivalent co-localization pattern with
lysotracker (Fig. 5B). Therefore, the stimulatory capacity of
native P6 can be accounted for by its enhanced uptake in DCs.
TLR2 expression mediates co-stimulatory molecule
upregulation in response to P6
In order to activate naı ¨ve T cells, APC must upregulate surface
expression of co-stimulatory molecules. We next examined what
role the lipid motif of P6 and signaling via TLR2 played in the
ability of P6-stimulated DC to express co-stimulatory molecules.
BMDCs from WT and TLR2
2/2 mice were cultured with native
P6 and non-lipidated rP6 overnight. Relative surface expression
levels of CD40 (Fig. 6) and CD86 was evaluated via two-color
flow cytometry. An approximate two-fold increase in the percent
of CD40
+ cells was observed in native P6 stimulated WT BMDCs
compared to TLR2
2/2 BMDCs. Neither WT or TLR2
2/2
BMDCs upregulated CD40 expression when stimulated with non-
lipidated rP6, thus demonstrating the synergy between lipoprotein
and TLR2 signaling for APC maturation. Data from relative
surface expression of CD86 revealed a far greater dependence on
the lipid motif and presence of TLR2 signaling (Table 1). The
absence of the lipid motif on rP6 resulted in lack of CD86
upregulation, compared to native P6. TLR2
2/2 BMDCs were
incapable of upregulating CD86 in response to any form of the P6
protein, but were responsive to formalin-killed NTHI which
expressed other TLR ligands.
Secretion of inflammatory cytokines IL-6 and TNF-a by
stimulated BMDCs provided the most striking evidence supporting
the requirement of both the lipid motif and TLR2 for APC
maturation. Levels of cytokines from stimulated BMDCs were
measured by Luminex multi-array (Table 2). WT and TLR2
2/2
BMDCs produced low levels of IL-6 and TNF-a in the presence of
media control. Native P6 induced potent secretion of inflamma-
tory cytokines from WT BMDCs. Although stimulation with non-
lipidated rP6 resulted in secretion of IL-6 and TNF-a above
background, the amount of cytokine secreted was 10-fold lower
compared to the levels from cells stimulated with native P6.
Expression of TLR2 on the BMDC was important for secretion of
IL-6 and TNF-a, as TLR2
2/2 BMDCs did not secrete these
cytokines to the same extent as WT BMDCs. Further, in the
absence of both the lipid motif and TLR2, BMDCs were unable to
secrete either of the cytokines assayed. However, TLR2
2/2
BMDCs were able to produce cytokines when stimulated with
formalin-killed NTHI, most likely due to the presence of LOS a
Figure 3. Lipid motif on P6 augments T cell proliferation and cytokine production. WT mice were immunized s.c. with 40 mg of native P6
emulsified in CFA and IFA one week later. (A) Proliferation of CD3
+ cells isolated from draining lymph nodes was measured following 4 day co-culture
with syngeneic irradiated BMDCs pulsed with 0.25, 0.12, and 0.06 mg/ml native P6 (&) or non-lipidated rP6 (N). Media alone control (m) was
performed for background proliferation of T cells. Thymidine was added to the wells for the last 16 hrs of incubation. (B) Splenocytes from the same
animals were co-cultured overnight with 0.06 mg/ml antigen pulsed irradiated BMDCs in ELISPOT plates coated with anti-cytokine mAb. Plates were
developed and spots enumerated microscopically. *p,0.01 1way ANOVA with Bonferroni post-test comparison of native P6 to non-lipidated rP6.
doi:10.1371/journal.pone.0019781.g003
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tion is therefore dependent on the presence of a lipid motif on P6
and the ability of APC to recognize this motif via TLR2.
TLR2 expression is important for antibody and recall
cytokine responses against P6
The role of TLR2 in eliciting in vivo adaptive immune responses
against P6 was evaluated. WT and TLR2
2/2 mice were imm-
unized with native P6, and the magnitude and kinetics of anti-P6
Ig in sera was monitored (Fig. 7A). WT mice produced very high
titers of anti-P6 Ig following immunization, whereas anti-P6
antibodies made by TLR2
2/2 mice were significantly lower at all
time points. Therefore, it is reasonable to conclude that expression
of the endogenous lipid motif on P6 and recognition of this motif by
TLR2 is required for effective immunization. Splenocytes were
assayed directly ex vivo 16 weeks after the initial immunization and
also following a 3 day restimulation in vitro in order to measure the
frequency of IFN-c, IL-2, or IL-4-secreting P6-specific T cells by
ELISPOT(Fig. 7B–D). The frequency ofcytokine-secretingT cells
directly ex vivo in both WT and TLR2
2/2 mice was low, but
expected, given the protracted time interval (16 weeks) between the
last exposure to antigen in vivo and analysis ex vivo. Splenocytes from
WT mice exhibited robust recall responses when restimulated
in vitro with P6, as the frequency of IFN-c, IL-2, and IL-4 secreting
T cells increased. In contrast, splenocytes from TLR2
2/2
mice exhibited poor recall responses even following in vitro
restimulation with P6. These data reinforce the notion that optimal
adaptive immune responses to the P6 antigen require the presence
of the lipid motif on the lipoprotein and the cognate receptor (i.e.
TLR2) for transduction of the signal.
Figure 4. Expression of TLR2 on APCs mediates responses to
lipoprotein P6. WT mice were immunized s.c. with 40 mg of native P6
emulsified in CFA and IFA one week later. (A) Proliferation of CD3
+ cells
isolated from draining lymph nodes was measured following 4 day co-
culture with syngeneic irradiated WT (black) and TLR2
2/2 (gray) BMDCs
pulsed with 0.06 mg/ml native P6 or non-lipidated rP6. Thymidine was
added to the wells for the last 16 hrs of incubation. (B) BMDCs from WT
(black bar) and TLR2
2/2 (gray bar) mice were incubated for 1 hr with
the indicated stimuli and Dextran-FITC simultaneously (formalin-killed
NTHI, f.k.). Cells were harvested and stained with anti-CD11c PE and
acquired by two-color flow cytometry (FITC vs PE) to determine
endocytic uptake of Dextran-FITC. Results are expressed as percent
change in FITC MFI from media control. *p,0.01 1way ANOVA with
Bonferroni post-test comparison of WT to TLR2
2/2.
doi:10.1371/journal.pone.0019781.g004
Figure 5. Enhanced endocytosis of lipid-expressing P6 by
BMDCs. BMDCs from WT mice were incubated overnight with Cy3-
conjugated native P6 or non-lipidated rP6. Cells were incubated with
100 mM LysoTracker Red for 30 min prior to harvest and then stained
with anti-CD11c FITC. (A) Representative image analysis of Cy3-
conjugatedendocytosisandco-localizationwithLysoTrackerforbacterial
P6 (top row) and non-lipidated rP6 (bottom row). (B) Percent of CD11c
+
BMDCs that endocytosed Cy3-conjugated antigen and co-localize with
LysoTracker. (C) Amount of endocytosed antigen present in Cy3
+ cells as
determined by Cy3 mean fluorescent intensity (MFI). (D) Antigen uptake
byBMDCsdetermined bytwo-color flowcytometry(FITCvsCy3). Percent
of CD11c
+ cells that have endocytosed Cy3-conjugated antigen over
unstimulated BMDCs are provided in each plot, in addition to MFI.
doi:10.1371/journal.pone.0019781.g005
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induction of high titers of anti-P6 antibodies
Based on the complementary results obtained from immuniza-
tion with non-lipidated rP6 in WT mice and native P6
immunization in TLR2
2/2 mice, we reasoned that optimal
stimulation with P6 required the direct conjugation of the lipid
motif to the antigen. In order to test the necessity of having a
directly conjugated lipid motif on P6 during immunization, non-
lipidated rP6 was given to WT mice in the absence or presence of
exogenous lipid, Pam3Cys. Equivalent amounts of Pam3Cys and
non-lipidated rP6 were injected; separate emulsions of Pam3Cys
and non-lipidated rP6 were generated but were injected
simultaneously. With this experimental design, it is possible to
directly test whether anti-P6 responses can be generated when the
lipid motif is not conjugated to the vaccine antigen but is present in
the vaccine formulation. Data from Figure 1 is presented again in
Figure 8A for ease of comparing to the anti-P6 Ig titers obtained
in mice immunized with non-lipidated rP6 plus Pam3Cys to mice
immunized with non-lipidated rP6 alone. The presence of
Pam3Cys at the time of immunization with non-lipidated rP6
elicited higher titers of total anti-P6 compared to immunization
without the lipid motif. The levels did not approach those
observed in native P6 immunization, but suggested that the
presence of the exogenously added lipid motif partially rescued the
diminished titers resulting from immunization with non-lipidated
rP6 alone. Additionally, the repertoire of anti-P6 IgG subclasses
was similar in mice immunized with native P6 or non-lipidated
rP6 plus Pam3Cys (data not shown). Therefore, the presence of the
Pam3Cys motif during immunization with the non-lipidated
antigen is able to enhance the magnitude and the nature of the
antibody response. Along with the enhancement of antibody
responses, the presence of the recombinant lipid motif generated
unbiased cytokine-secreting T cells at similar frequencies as in
mice immunized with native P6 (Fig. 8B–D). Collectively our
data establish that the presence of the lipid motif is crucial for
Figure 6. TLR2 expression on APC mediates upregulation of CD40 in response to lipoprotein P6. BMDCs from WT (top row) and TLR2
2/2
(bottom row) mice were incubated overnight with the indicated stimuli. Cells were harvested and stained with anti-CD11c and anti-CD40 and
acquired by two-color flow cytometry (FITC vs PE) to determine CD40 expression patterns. Percent of cells expressing CD40 over isotype are provided
in each plot. *p,0.05 2way ANOVA with Bonferroni post-test comparison of native P6 between WT and TLR2
2/2.
{p,0.05 2way ANOVA with
Bonferroni post-test comparison of native P6 and non-lipidated rP6 in WT.
doi:10.1371/journal.pone.0019781.g006
Table 1. Co-stimulatory molecule expression on BMDCs.
a
Media
Native
P6
Non-lipidated
rP6 NTHI (f.k.)
CD40 WT 09.460.2 024.9601.3* 11.560.8
{ 041.4603.8
TLR2
2/2 09.360.1 012.0601.7* 08.860.3
{ 035.0608.8
CD86 WT 26.862.8 100.7612.7* 39.965.6
{ 254.0667.9
TLR2
2/2 30.962.3 038.1603.7* 29.361.7
{ 200.9639.3
aMean fluorescence intensity 6 SEM of anti-CD40 and anti-CD86 staining on WT
and TLR2
2/2 BMDCs.
*p,0.05 2way ANOVA with Bonferroni post-test comparison of native P6
between WT and TLR2
2/2.
{p,0.05 2way ANOVA with Bonferroni post-test comparison of bacterial P6 and
non-lipidated rP6 in WT.
doi:10.1371/journal.pone.0019781.t001
Table 2. Inflammatory cytokine secretion by BMDCs.
a
Media
Native
P6
Non-lipidated
rP6 NTHI (f.k.)
IL-6 WT 77 15,000 1,004 91,050
TLR2
2/2 22 01,270 0,031 31,400
TNF-a WT 19 01,130 0,127 02,395
TLR2
2/2 14 00,151 0,029 02,840
aIL-6 and TNF-a secretion (pg/ml) by WT and TLR2
2/2 BMDCs.
doi:10.1371/journal.pone.0019781.t002
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generated when the motif is directly conjugated to the protein
antigen.
Discussion
In this study, we undertook a systematic analysis of the
contribution of the lipid motif of lipoprotein antigen P6 to its
ability to stimulate both innate and adaptive immune responses.
As this lipoprotein is a key component required for maintaining
the cellular integrity of the outer membrane in NTHI, it is to no
surprise that P6 is highly conserved among several NTHI strains
[8]. Furthermore, several lines of evidence indicate that P6 induces
protective immune responses in humans indicating that the
protein is a promising vaccine candidate for otitis media and
COPD. In evaluating the role of the lipid motif in P6, our studies
have highlighted the pivotal role of this motif in determining the
immunogenicity of P6.
It is clear that TLR ligands help shape immune outcomes, both
in the setting of vaccination and infection. In addition to creating
robust immune responses, TLR ligands are also involved in the
skewing of protective immunity upon vaccination. Using a
recombinant Salmonella vaccine in MyD88
2/2 mice, it was
shown that CD4
+ T cells and iNKT cells were impaired in their
ability to provide help for Th1-dependent antibody responses [15].
The effect of TLR ligation is often observed in the programming
of DC towards a phenotype that stimulates naı ¨ve T cells and
secretion of pro-inflammatory cytokines. The P6 vaccine antigen
we have investigated demonstrates a unique ability to induce non-
skewed adaptive immune responses via the activation of
stimulatory DC.
Immunization with purified native P6 elicited very robust titers
of antibodies that were durably sustained (up to 16 weeks) after the
initial antigen injection and the high antibody titers reveal the
potent immunogenicity of this lipoprotein. The repertoire of IgG
subclasses elicited by native P6 suggests that not only was the
immunization robust but also the response was unbiased, as all
four major IgG subclasses were present at substantial levels in the
sera. Unbiased antibody repertoire generation is an appealing
feature of a bacterial vaccine antigen. Activation of TLR signals on
DC during vaccination instruct the generation of effector and
memory lymphocytes [1,16]. The phenotype and TLR expression
pattern of the DC that responds to the NTHI infection may skew
the response to either Th1 or Th2, thus a vaccine that can elicit
both types of memory T cells will be ideally suited for a rapid
response in the face of infection. Ligands for TLR2 have been
shown to stimulate both Type 1 (e.g. IgG2a) and Type 2 (e.g.
IgG1) immune responses [17–21]. Generation of skewed antibody
responses elicited by non-lipidated rP6 probably reflect the
contribution of the protein component. The use of Pam3Cys as
an adjuvant is often associated with Type 2 responses, although
other groups have also demonstrated the production of IFN-c
Type 1 responses [22,23].
The immunogenicity of P6 is facilitated by the presence of a
CD4 helper T cell epitope [13,24,25]. The presentation of the
epitope to P6-specific CD4
+ T cells is likely enhanced by the
Figure 7. TLR2 expression is important for antibody and recall cytokine responses against P6. WT (black bar) and TLR2
2/2 (gray bar)
mice were immunized i.p. with 40 mg of native P6 emulsified in CFA, IFA, and PBS. (A) Anti-P6 Ig levels were measured in pre-immune and post-
immune sera by ELISA. (B–D) Frequency of cytokine secreting T cells in spleens from the same animals after 16 weeks were measured by ELISPOT.
Splenocytes were assayed directly ex vivo and after 3 day restimulation with BMDCs pulsed with native P6. Plates were developed and spots
enumerated microscopically. *p,0.05 2way ANOVA with Bonferroni post-test comparison of WT and TLR2
2/2.
doi:10.1371/journal.pone.0019781.g007
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APC upon recognition by TLR2. Using a fluorophore-conjugated
P6, enhanced rates of endocytosis were observed for the lipid
motif-expressing antigen; thus TLR2-mediated targeting of the
antigen impacts on the amount of antigen that an APC is likely to
process and present to antigen-specific T cells. This ensures that
the DC which endocytose the P6 antigen mature into a
professional APC capable of presenting the helper epitope. Thus,
antigen presentation of the helper epitope is localized in the same
APC that has been stimulated by the TLR2 ligand. There was the
theoretical possibility that other potential TLR2 ligands, such as
peptidoglycan [26], which could be present in very small
contaminating quantities during P6 purification could potentially
contribute to the robust production of IL-6 in TLR2 expressing
DCs. However, our experimental approach using both the TLR2-
deficient APCs and non-lipidated rP6, would strongly suggest that
the immunostimulatory capacity of bacterial P6 is dominated by
this antigen and not other contaminating molecules during
purification.
Lipopeptides have been utilized as adjuvants in several vaccine
models [27–31]. This is due to their ability to bind TLRs present
on antigen presenting cells, leading to their maturation and
subsequent activation of helper T cells and antibody producing B
cells. Adjuvant use of lipopeptides elicits both Th1 and Th2
cytokines depending on the model antigen used in immunizations
[30,32]. TLR-mediated activation of innate immune cells leads to
the robust stimulation of adaptive immune lymphocytes, although
the mechanism by which this occurs varies greatly in each
individual model. The lipid motif on P6 is required for recognition
by TLR2 expressed on DCs and leads to a robust stimulation of T
cells in vivo. Activation of NF-kB signaling results from ligation of
TLR2 by P6 and therefore accounts for the upregulation of surface
co-stimulatory molecules and secretion of inflammatory cytokines
[33,34]. We have observed robust production of IL-6 and TNF-a
from TLR2-expressing APCs stimulated with native P6, suggesting
that NF-kB signaling is activated and leads to cytokine secretion.
Production of these cytokines, among others, is critical for the
activation of T cells.
TLR agonists are used as adjuvants in many vaccine
formulations to enhance immune responses; however, the
contribution of TLR signaling for the generation and maintenance
of antibodies remains controversial. Pasare et al showed evidence
for TLR requirement in eliciting an antibody response, but in a
separate study, Gavin et al utilized mice devoid of TLR signaling to
produce antibody responses against TLR ligand-free antigens
[35,36]. Recently, intrinsic TLR signals in B cells were
demonstrated to enhance antibody responses, but were dispens-
able for their induction [37]. TLR signals could be involved at
various points of B cell activation, through either directly signaling
on the B cells during antigen recognition or indirectly following
DC-mediated T helper responses. Though B cells require help
from CD4
+ T cells in order to initiate effector functions, such as
immunoglobulin class switching, the expression of surface TLR2
on B cells could result in the direct activation of P6-specific B cells.
Figure 8. Direct conjugation of lipid motif on P6 is important for induction of high titers of anti-P6 antibodies and cytokine
secretion by antigen-secretion T cells. WT mice were immunized i.p. with 40 mg of native P6 (&), non-lipidated rP6 (N), or non-lipidated rP6 plus
Pam3Cys (open circle) emulsified in CFA, IFA, and PBS. (A) Anti-P6 Ig levels were measured in pre-immune and post-immune sera by ELISA. (B–D)
Frequency of cytokine secreting T cells in spleens from the same animals after 16 weeks were measured by ELISPOT. Splenocytes were assayed
directly ex vivo and after 3 day restimulation with BMDCs pulsed with native P6. Plates were developed and spots enumerated microscopically.
*p,0.05 2way ANOVA with Bonferroni post-test comparison.
doi:10.1371/journal.pone.0019781.g008
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the ensuing response can differ from the response elicited by TLR-
activated DCs [38,39]. The immune modulation of TLR
activation in B cells includes the secretion of cytokines that are
not produced by DCs, such as IL-10 and IFN-c [40,41]. The
direct activation of B cells during P6 immunization cannot be
discounted and may explain the production of the four P6-specific
IgG subclasses. The inclusion of TLR agonists has been shown to
be crucial for the generation of protective anti-RSV antibodies
following immunization with an inactivated vaccine [42]. TLR
signaling by the B cells directly leads to the production of long-
lived antibodies, suggesting that directing responses to B cells with
TLR agonists may be important for efficacious immunizations.
The lipid motif on P6 may stimulate T cells not only via DCs but
also likely through B cell activation. Immunization with the
MALP-2 lipopeptide has been shown to activate B cells directly via
TLR2 in the absence of CD4
+ T cell help. MALP-2 activated B
cells were capable of secreting IgM and IgG, but required CD4
+ T
cell in order to secrete IgA [43]. Immunization with P6 likely
activates the B cells directly due to the expression of TLR2 and
this response is further enhanced due to the presence of DC
stimulated CD4
+ T cells.
The importance of direct conjugation of Pam3Cys on the P6
antigen during immunization was highlighted by the modest
enhancement of antibody response when the TLR agonist was
admixed with non-lipidated rP6. Thus, in spite of utilizing excess
free Pam3Cys, the magnitude of antibodies generated to non-
lipidated rP6 plus exogenous lipid motif was markedly lower than
the response elicited to native P6 in which the lipid motif is directly
conjugated to the protein. Other TLR agonists have been used as
fusions or admixed with protein antigens for effective immuniza-
tions. Flagellin, the only known TLR5 ligand, has been conjugated
to Listeria p60, influenza virus matrix and hemagglutinin in order
to enhance immune responses to these antigens during vaccination
[44–46]. Admixing of flagellin with Plasmodium vivax MSP-1
protein generated strong responses to this novel malaria vaccine
[47]. Enhancement of immune responses with inclusion of flagellin
in the vaccine formulation, either by direct conjugation or
admixing, is likely due to its inherent stimulatory capacity.
Pam3Cys has also been used as an adjuvant in admixing vaccine
formulations; however, optimal responses to P6 require direct
conjugation of this TLR ligand. Based on our results, an effective
vaccine for NTHI that utilizes the conserved P6 protein in its
formulation, should include the Pam3Cys lipid motif, preferably
directly conjugated to the antigen, in order to elicit robust and
sustained activation of innate and adaptive immunity.
In this study, we have identified the role and mechanism of
action of the amino-terminal lipid motif on the lipoprotein P6 of
NTHI and demonstrated that the presence of this moiety on the
antigen during immunization resulted in production of high titers
of serum anti-P6 and robust activation of T cells. Lipidated P6
matured TLR2 expressing DCs, rendering these cells into potent
APC for P6-specific T cells. Recognition of the lipid motif in vivo by
TLR2 was also critical for the effective generation of anti-P6
antibodies and T cells. Taken together, this work has detailed the
underlying basis for the enhanced immunogenicity of the P6
lipoprotein. This notable feature of P6 can therefore be exploited
to improve vaccine formulations that utilize P6 for protection
against NTHI infections.
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